Register  /  Login      
  1. Home
  2. Chimica Oggi-Chemistry Today
  3. AN INTRODUCTION:
    Are we there yet?
    An update on oligonucleotide drug development
  4. AN INTRODUCTION: Are we ...
P. 35-38 /

AN INTRODUCTION:
Are we there yet?
An update on oligonucleotide drug development

KATHRYN L. ACKLEY

Vice President of Development,
Nitto Denko Avecia Inc.
8560
Reading Rd, Cincinnati, OH 45215 USA

ABSTRACT: Oligonucleotide therapeutics are a new class of drugs with only three commercialized drugs to date. In spite of this limited commercial success, the oligonucleotide field continues to grow rapidly.  Many drugs have advanced to late clinical phases. A variety of drug delivery strategies have proven effective, and improvements continue to be made in the manufacturing technologies used to produce oligonucleotides. Growth in the oligonucleotide field is fueled by the renewed interest of large pharmaceutical companies and the emergence of startup companies with new intellectual property. The oligonucleotide field appears to be poised for success.
KEYWORDS: Oligonucleotide therapeutics; solid phase oligonucleotide synthesis; drug development; drug delivery.


INTRODUCTION
Oligonucleotide therapeutics have tantalized drug developers with the promise of rational drug design, lower drug development costs, and the ability to reach targets that conventional small molecule drugs cannot. Three oligonucleotide drugs have been approved by regulators, but oligonucleoti ...
...
...
Forgot password?
Don't have an account?
Register now.

View the issue


AN INTRODUCTION:
Are we there yet?
An update on oligonucleotide drug development
You may be interested in: